A month has gone by since the last earnings report for Krystal Biotech, Inc. (KRYS Quick QuoteKRYS - Free Report) . Shares have added about 12% in that time frame, outperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Krystal Biotech due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts.

Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus

Krystal reported second-quarter 2026 earnings per share (EPS) of $1.79, which surpassed the Zacks Consensus Estimate of $1.70. The company recorded an EPS of $1.29 in the year-ago quarter.

Revenues of $119.2 million rose 24.14% year over year in the reported quarter, marginally beating the Zacks Consensus Estimate of $119 million. Revenues came in solely from Vyjuvek sales.

Q2 Results in Detail

The top line comprises product revenues from Krystal’s only marketed drug, Vyjuvek.

Krystal generated $119.2 million in product revenues from Vyjuvek, up from $96 million in the year-ago quarter, driven by strong patient uptake.

The gross margin in the reported quarter was 95%.

Research and development (R&D) expenses were approximately $14.5 million, including stock-based compensation and where roughly consistent with the prior-year quarter. Selling, general and administrative (SG&A) expenses totaled $39.9 million, including stock-based compensation, up 13.6% from the year-ago level. This increase was primarily due to increased headcount and marketing costs to support the global launches of Vyjuvek.

As of June 30, 2026, cash, cash equivalents and investments totaled $1.1 billion compared with approximately $1 billion as of March 31, 2026.

KRYS’ 2026 Guidance

Krystal reiterated its non-GAAP combined R&D and SG&A expense guidance of $175 million to $195 million for full-year 2026.

How Have Estimates Been Moving Since Then?

Since the earnings release, investors have witnessed a upward trend in estimates review.

VGM Scores

At this time, Krystal Biotech has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock has a grade of D on the value side, putting it in the bottom 40% for value investors.

Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook

Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Krystal Biotech has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry Player

Krystal Biotech belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Astrazeneca (AZN Quick QuoteAZN - Free Report) , has gained 4.4% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.

Astrazeneca reported revenues of $15.38 billion in the last reported quarter, representing a year-over-year change of +6.4%. EPS of $2.63 for the same period compares with $2.18 a year ago.

For the current quarter, Astrazeneca is expected to post earnings of $2.60 per share, indicating a change of +9.2% from the year-ago quarter. The Zacks Consensus Estimate has changed -1.3% over the last 30 days.

Astrazeneca has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.